Charles River Laboratories International, Inc. (NYSE:CRL) today reported third-quarter 2005 financial results. Net sales for the third quarter of 2005 increased 55.6% to $273.9 million, compared to $176.0 million reported in the third quarter of 2004. The increase was due primarily to the acquisition of Inveresk Research Group, and also to continuing strong demand for outsourced preclinical services.
